IgE and eosinophils as therapeutic targets in asthma

Tanvi R. Patel, Sanjiv Sur

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Purpose of review Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively. The purpose of this review is to analyze the advancements in currently available biologic therapies targeted at IgE and eosinophils in asthma and to identify how these therapies may impact overall healthcare costs. Recent findings Omalizumab is an anti-IgE antibody that is approved for use of poorly controlled moderate-to-severe asthma. Many studies have confirmed that omalizumab not only improves quality of life and symptom scores, but also decreases urgent care and emergency department visits and hospitalizations. Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease. Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils. For patients with poorly controlled eosinophilic asthma, these biologic agents improve asthma symptoms, reduce exacerbations, and reduce emergency visits and hospitalizations. Summary Poorly controlled severe asthma affects a small portion of patients with asthma in the United States and yet it accounts for large portion of healthcare utilization. Biological therapies in poorly controlled severe persistent asthma have been identified to reduce healthcare utilization, including emergency visits and hospitalizations. Biologic agents have a clear beneficial role in the management of severe asthma, and further evaluations should be continued in identifying optimal patient characteristics for the various agents and overall benefit toward healthcare utilization and cost.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume17
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Eosinophils
Immunoglobulin E
Asthma
Biological Factors
Biological Therapy
Therapeutics
Health Care Costs
Hospitalization
Emergencies
Cytokines
Delivery of Health Care
Interleukin-5
Ambulatory Care
Hospital Emergency Service
Quality of Life

Keywords

  • Biologic targets in asthma
  • Eosinophils
  • IgE
  • Severe asthma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

IgE and eosinophils as therapeutic targets in asthma. / Patel, Tanvi R.; Sur, Sanjiv.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 17, No. 1, 2017, p. 42-49.

Research output: Contribution to journalReview article

Patel, Tanvi R. ; Sur, Sanjiv. / IgE and eosinophils as therapeutic targets in asthma. In: Current Opinion in Allergy and Clinical Immunology. 2017 ; Vol. 17, No. 1. pp. 42-49.
@article{88c8f6cd64fc473f9fac873587aeb7b1,
title = "IgE and eosinophils as therapeutic targets in asthma",
abstract = "Purpose of review Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively. The purpose of this review is to analyze the advancements in currently available biologic therapies targeted at IgE and eosinophils in asthma and to identify how these therapies may impact overall healthcare costs. Recent findings Omalizumab is an anti-IgE antibody that is approved for use of poorly controlled moderate-to-severe asthma. Many studies have confirmed that omalizumab not only improves quality of life and symptom scores, but also decreases urgent care and emergency department visits and hospitalizations. Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease. Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils. For patients with poorly controlled eosinophilic asthma, these biologic agents improve asthma symptoms, reduce exacerbations, and reduce emergency visits and hospitalizations. Summary Poorly controlled severe asthma affects a small portion of patients with asthma in the United States and yet it accounts for large portion of healthcare utilization. Biological therapies in poorly controlled severe persistent asthma have been identified to reduce healthcare utilization, including emergency visits and hospitalizations. Biologic agents have a clear beneficial role in the management of severe asthma, and further evaluations should be continued in identifying optimal patient characteristics for the various agents and overall benefit toward healthcare utilization and cost.",
keywords = "Biologic targets in asthma, Eosinophils, IgE, Severe asthma",
author = "Patel, {Tanvi R.} and Sanjiv Sur",
year = "2017",
doi = "10.1097/ACI.0000000000000336",
language = "English (US)",
volume = "17",
pages = "42--49",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - IgE and eosinophils as therapeutic targets in asthma

AU - Patel, Tanvi R.

AU - Sur, Sanjiv

PY - 2017

Y1 - 2017

N2 - Purpose of review Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively. The purpose of this review is to analyze the advancements in currently available biologic therapies targeted at IgE and eosinophils in asthma and to identify how these therapies may impact overall healthcare costs. Recent findings Omalizumab is an anti-IgE antibody that is approved for use of poorly controlled moderate-to-severe asthma. Many studies have confirmed that omalizumab not only improves quality of life and symptom scores, but also decreases urgent care and emergency department visits and hospitalizations. Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease. Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils. For patients with poorly controlled eosinophilic asthma, these biologic agents improve asthma symptoms, reduce exacerbations, and reduce emergency visits and hospitalizations. Summary Poorly controlled severe asthma affects a small portion of patients with asthma in the United States and yet it accounts for large portion of healthcare utilization. Biological therapies in poorly controlled severe persistent asthma have been identified to reduce healthcare utilization, including emergency visits and hospitalizations. Biologic agents have a clear beneficial role in the management of severe asthma, and further evaluations should be continued in identifying optimal patient characteristics for the various agents and overall benefit toward healthcare utilization and cost.

AB - Purpose of review Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively. The purpose of this review is to analyze the advancements in currently available biologic therapies targeted at IgE and eosinophils in asthma and to identify how these therapies may impact overall healthcare costs. Recent findings Omalizumab is an anti-IgE antibody that is approved for use of poorly controlled moderate-to-severe asthma. Many studies have confirmed that omalizumab not only improves quality of life and symptom scores, but also decreases urgent care and emergency department visits and hospitalizations. Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease. Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils. For patients with poorly controlled eosinophilic asthma, these biologic agents improve asthma symptoms, reduce exacerbations, and reduce emergency visits and hospitalizations. Summary Poorly controlled severe asthma affects a small portion of patients with asthma in the United States and yet it accounts for large portion of healthcare utilization. Biological therapies in poorly controlled severe persistent asthma have been identified to reduce healthcare utilization, including emergency visits and hospitalizations. Biologic agents have a clear beneficial role in the management of severe asthma, and further evaluations should be continued in identifying optimal patient characteristics for the various agents and overall benefit toward healthcare utilization and cost.

KW - Biologic targets in asthma

KW - Eosinophils

KW - IgE

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85001052538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001052538&partnerID=8YFLogxK

U2 - 10.1097/ACI.0000000000000336

DO - 10.1097/ACI.0000000000000336

M3 - Review article

C2 - 27906698

AN - SCOPUS:85001052538

VL - 17

SP - 42

EP - 49

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 1

ER -